Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO precision immunosuppressive drug monitoring in liver transplantation
2025-523563-38-00Phase 4Authorised
- Sponsor
- CHU Rennes
- Start
- Oct 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus and mycophenolic acid (2 arms), sponsored by CHU Rennes. Primary endpoint: Primary composite endpoint at 1 year. Planned start Oct 2026; status: authorised.
02
Drugs
tacrolimusmycophenolic acid
Beyond the preview
Go deeper on 2025-523563-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523563-38-00.